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Abstract
Deletion of the first exon of calmodulin-lysine N-methyltransferase (CaM KMT, previously C2orf34) has been reported in two
multigene deletion syndromes, but additional studies on the gene have not been reported. Here we show that in the cells
from 2p21 deletion patients the loss of CaM KMT expression results in accumulation of hypomethylated calmodulin
compared to normal controls, suggesting that CaM KMT is essential for calmodulin methylation and there are no
compensatory mechanisms for CaM methylation in humans. We have further studied the expression of this gene at the
transcript and protein levels. We have identified 2 additional transcripts in cells of the 2p21 deletion syndrome patients that
start from alternative exons positioned outside the deletion region. One of them starts in the 2nd known exon, the other in
a novel exon. The transcript starting from the novel exon was also identified in a variety of tissues from normal individuals.
These new transcripts are not expected to produce proteins. Immunofluorescent localization of tagged CaM KMT in HeLa
cells indicates that it is present in both the cytoplasm and nucleus of cells whereas the short isoform is localized to the Golgi
apparatus. Using Western blot analysis we show that the CaM KMT protein is broadly expressed in mouse tissues. Finally we
demonstrate that the CaM KMT interacts with the middle portion of the Hsp90 molecular chaperon and is probably a client
protein since it is degraded upon treatment of cells with the Hsp90 inhibitor geldanamycin. These findings suggest that the
CaM KMT is the major, possibly the single, methyltransferase of calmodulin in human cells with a wide tissue distribution
and is a novel Hsp90 client protein. Thus our data provides basic information for a gene potentially contributing to the
patient phenotype of two contiguous gene deletion syndromes.
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Introduction
CaM KMT (previously C2orf34) has been reported to be within
the deletion region of two autosomal, recessive syndromes. The
first reported, 2p21 deletion syndrome is caused by a homozygous
deletion of 179,311 bp on chromosome 2p21, which includes the
type I cystinuria gene (SLC3A1), the protein phosphatase 2Cb
gene (PPMB1), prolylendopeptidase like (PREPL) gene, and the
first exon of the CaM KMT gene. Patients homozygous for this
deletion present with cystinuria, neonatal seizures, hypotonia,
severe mental and growth retardation, facial dysmorphism and
reduced activity of all, except the 2nd mitochondrial encoded
respiratory chain enzymatic complexes [1,2]. The second disorder
is atypical hypotonia-cystinuria syndrome (HCS) caused by
a smaller deletion of 77.4 kb on the 2p21 chromosome that
encompasses SLC3A1, PREPL and similarly to the first report the
first exon of CaM KMT. Atypical HCS patients present with
a phenotype partly similar to 2p21 deletion syndrome such as
severe hypotonia at birth, poor feeding, facial dysmorphism,
growth retardation and cystinuria but with growth hormone
deficiency not observed in the patients of the 2p21 deletion
syndrome [3]. In addition, they showed a mild to moderate mental
retardation and cytochrome C oxidase deficiency (mitochondrial
complex IV) [4].
We have previously shown that CaM KMT is transcribed in
a wide range of human tissues whereas the loss of the first exon
abolished the transcription in the cells of 2p21 deletion patients
[2]. Recently, we identified CaM KMT as a class I, non-SET
domain calmodulin-lysine N-methyltransferase that catalyzes the
formation of a trimethyllysyl residue at position 115 in calmodulin
[5].
Calmodulin (CaM) is a ubiquitous calcium-binding protein that
regulates a multitude of different protein targets. It is a major
transducer of calcium signaling that sets the free Ca2+ level by
binding calcium ions more rapidly than other Ca2+-binding
proteins [6]. CaM is frequently trimethylated at Lys-115 and its
methylation status changes at different developmental stages as
well as in tissue specific manners that potentially modulate its
actions [5].
Aiming to better characterize CaM KMT and its potential
contribution to the 2p21 deletion syndrome, we demonstrate
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alternative transcription from the CaM KMT exons outside the
2p21 deletion syndrome, but they are not likely to be translated,
the accumulation of hypomethylated calmodulin in patients
compared to normal controls suggesting that CaM KMT plays
a pivotal role in calmodulin methylation and also that there are no
compensatory mechanisms for CaM methylation in humans.
Furthermore, cellular localization studies revealed that the full-
length CaM KMT localizes to the cytoplasm and nucleus in
accordance with a similar subcellular distribution of calmodulin,
whereas the short variant of CaM KMT (CaM KMTsh) that lacks
the methyltransferase domain is localized to the Golgi complex.
Western blot analysis showed expression of the CaM KMT variant
in various mouse tissues. Furthermore we show that Hsp90 a highly
conserved molecular chaperone [7] required for the late-stage
folding of a number of classes of proteins referred to as client
proteins, interacts through its middle domain with Cam KMT.
Client proteins depend on Hsp90 function for the correct folding,
maturation and become deregulated upon limited Hsp90 activity
[8], and CaM KMT relies on Hsp90 chaperone activity for its
stability since geldanamycin [9] treatment of HeLa cells
transfected with CaM KMT resulted in a geldanamycin concen-
tration dependent decrease in CaM KMT. These data indicate
that CaM KMT is a novel client protein for Hsp90 and provide
a new connection between Hsp90 chaperon function and CaM
methylation.
Materials and Methods
Cell Culture
HeLa, COS-7 and HEK293 cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM), supplemented
with 10% fetal calf serum and 2 mM L-glutamine, 100 U/ml
penicillin, 0.1 mg/ml streptomycin, 12.5 mg/ml nystatin, at 37uC
in humidified atmosphere of 5% CO2. Lymphoblastoid cell lines
from 2p21 deletion patients and normal individuals (approved by
the Soroka Medical Center IRB and participants provided written
informed consent) were maintained at a logarithmic growth phase
in 1640 RPMI supplemented with 10% fetal calf serum, 2 mM
glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin,
12.5 mg/ml nystatin and 2.5 mg/ml Amphotericin B at 37uC in
humidified atmosphere of 5% CO2.
Constructs
Preparation of mammalian expression vectors for CaM KMT
with C-terminal GFP tag: GFP-CaM KMTsh mammalian
expression vector was constructed by PCR amplification using
pDNR-LIB-CaM KMTsh as a template and the following forward
and reverse primers: 59CGGAATTCA AATGGAGTCGC-
GAGTCG39; 59ACGCGTCGAC-
CATTTTCCCCTGGTTGCTT39 subcloned into the EcoRI
and SalI sites of pEGFPN1 plasmid (Clontech). The GFP-CaM
KMT full length variant was subcloned into the XhoI and EcoRI
of pEGFPN1 plasmid (Clontech) by PCR amplification using
pGEX-5X-1-CaM KMT construct as a template and the primers:
forward-59CTCGAGATGGAGTCGCGAGTCG39, reverse-
59GAATTCGCTTTC CATGTTTGGTC39. Preparation of
mammalian expression vector for CaM KMT with N-terminal
Myc-tag: The CaM KMT was amplified by PCR using FLAG-
CaM KMT construct as a template, with the primers: forward-
59TTAGAATTCAT GGAGTCGCGAGTCGCG39, reverse-
59TTACTCGAGCTATCCATGTT TGGTCAAAAT39. The
PCR product was subcloned into the EcoRI and XhoI sites of
pCan expression plasmid. Cloning of the CaM KMT into
bacterial expression vector pGEX-5X-1 with N-terminal GST
tag: GST-CaM KMT was restriction digested out of pFLAG-
CMV5a-CaM KMT with EcoRI enzyme and ligation into the
EcoRI site of the pGEX-5X-1 plasmid. GST-CaM KMTsh was
subcloned into the EcoRI and XhoI of the pGEX-5X-1 vector by
PCR amplification using GFP-CaM KMTsh as a template and the
primers- forward-59GAATTCATGGAGTCGCGAGT CG39; re-
verse-59CTCGAGTCATTTTCCCCT GGTTGC39. All con-
structs were verified by DNA sequencing on an ABI PRISM
3100 DNA Analyzer with the BigDye Terminator v. 1.1 Cycle
Sequencing Kit according to the manufacturer’s protocol (Applied
Biosystems, CA, USA). GST-Hsp90 C, M, N terminal domains
were a kind gift from professor F. Ulrich Hartl, Max-Planck-
Institute of Biochemistry, Munich, Germany.
Transient Transfection
All transfections were performed using TransIT-LT1 reagent
(Mirus). For Western blots and immunoprecipitation experi-
ments, cells were plated at density of 26106 and 16105 cells
per 100 mm plate and per 1 well of 6-well plate respectively, 24
hours prior to transfection. Cells were harvested 24–48 hours
after transfection.
Antibodies
The anti-Myc monoclonal, anti-FLAG monoclonal (M2), anti-
GFP antibodies were purchased from Sigma-Aldrich. The anti-
Hsp90 alpha/beta (F-8), anti-GAPDH antibodies were obtained
from Santa Cruz Biotechnology. Peroxidase (HRP) - conjugated
whole IgG secondary antibodies, and Cy3, Cy2-conjugated
secondary immunofluorescence antibodies were from Jackson
Immunoresearch Laboratories. Anti-CaM KMT polyclonal anti-
bodies were raised in rabbits by immunization with a GST-CaM
KMT fusion proteins followed by affinity purification. The anti-
CaM antibody raised in mouse was purchased from Invitrogen.
The AP-conjugated IgG secondary antibody specific for mouse
was from BioRad.
CaM KMT Polyclonal Antibody Production
CaM KMT polyclonal antibodies were generated by immu-
nizing two New Zealand white rabbits with GST-CaM KMT
fusion protein. Subcutaneous injection of 1 ml of antigen
solution containing approximately 100 mg of the purified
recombinant proteins, using Freund’s complete adjuvant were
done for the initial immunization. The antigens were injected as
native and denatured proteins to produce antibodies that would
be useful for Western and immunoprecipitation experiments.
Rabbit serum was collected before immunization as a negative
control. Three boosts were given with intervals of 3 to 5 weeks,
using Freund’s incomplete adjuvant. Serum was collected 1
week after the last injection. All blood samples were refrigerated
for 16 h and centrifuged (450 6 g; 10 min) at room
temperature. The serum was introduced to further purification
[10] and stored at 280uC.
RNA Isolation and cDNA Preparation
Total RNA was isolated from lymphoblastoid cells using the
EZ-RNA Total RNA Isolation Kit (Biological Industries). Total
human RNA of different tissues was purchased from Clontech.
Reverse transcription was done using Reverse-iT 1st Strand
Synthesis kit (ABgene). The quality of the resulting cDNA has
been tested by the amplification of tubulin chaperone E gene with
the primers: forward-59AAAACGTCCATGTTCCCATC39; re-
verse-59CCCCAGACACGATAAGCAGT39.
Characterization of CaM KMT
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RT-PCR
RT-PCR was performed on 1–3 ml of cDNA, 0.5 mM of each
primer, 2.5 mM dNTP’s, Taq DNA polymerase (Fermentas).
Primer in exon 11: 59ATAAG CAGAAGCGGGTAATGA39,
primer in the new found exon: 59GCCTCAAACTCCT-
GAACTGC39, primer in exon 4 of the long isoform: 59GCAAC-
CATGAGCCCAGCCAAGC39.
RACE-PCR-SMART 59
RACE cDNA amplification kit (Clontech) was used to amplify
potential CaM KMT transcripts from lymphoblastoid cells of
patients and normal controls. For the first strand synthesis we used
the universal primer mix (UPM) as the forward primer and the
reverse primer was designed at the border of the 5th and 6th exons
of the long variant, to avoid priming in the residual DNA that may
be retained in the RNA preparation: 59GCACATTTCT-
GATGGCCTTTTCATTCC39.The product was then amplified
using nested PCR reaction with UPM and a reverse primer that
was located within the 4th exon of the long variant (presented in
the RT-PCR paragraph). The RACE products were cloned into
pGEM-T easy vector (Promega) and transformed into DH5a
strain of E.coli.
Fluorescence Imaging
Cells were grown on cover slips, fixed with freshly prepared 4%
paraformaldehyde/PBS for 15 minutes, then washed extensively
in PBS and mounted with Prolong Gold antifade reagent
containing DAPI (Invitrogene) on microscope slides. The samples
were visualized on a Leica DMR compound microscope equipped
for immunofluorescence and photographed with a Spot RT digital
camera (Diagnostic Instruments). Confocal fluorescent images
were obtained by a Zeiss LSM Axiovert 100 laser scanning
microscope.
Whole Cell Protein Extraction
Cells were collected by scraping, pelleted by centrifugation
and washed with cold PBS three times before lysis. To stabilize
transient and weak protein-protein interaction, the cells used for
immunoprecipitation were treated with formaldehyde (Sigma)
1% for 15 minutes and quenched with 1.25 M glycine/PBS
prior to collection [11]. The cells (16108 cells) were lysed in
1 ml modified RIPA buffer (50 mM Tris HCl, pH 8.0, 150 mM
NaCl, 1% NP40, 1 mM EDTA, protease inhibitors (Sigma)) for
20 min on ice, followed by centrifugation in an Eppendorf
microfuge for 20 minutes at 13000 rpm at 4uC to remove
insoluble debris. The supernatant was either used directly or
stored at 280uC.
Extraction of Mouse Tissues
The tissues from the ICR mice were frozen at 280uC and the
lysates were prepared immediately before the Western blot
experiment. The tissues were homogenized in RIPA buffer
50 mM Tris HCl, pH 8.0, 150 mM NaCl, 1% NP40, 0.5%
sodium deoxycholate, 0.1% SDS, 1 mM EDTA, protease in-
hibitor (Sigma) using Polytron-PT-2100 homogenizer. Tissue and
cell debris were removed by centrifugation at 4uC for 20 minutes,
12000 rpm. Protein concentration was determined with Bio-Rad
protein assay. The lysates were boiled for 5 min in 16SDS sample
buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% SDS, 0.01%
bromophenol blue, 5% b-mercaptoethanol) and 100 mg of
proteins were loaded. The purified antibodies were diluted 1:200
with 2.5% milk in TTBS, preimunne serum at 1:50 and anti-
HSP90 1:200 with 2.5% milk in TTBS. The samples with
formaldehyde crosslinking were boiled for 40 minutes, before they
were separated by SDS-PAGE.
Immunoprecipitation, Western Blot Analysis and
Coomassie Staining of SDS-PAGE
For immunoprecipitation, samples of 0.5–1 mg protein from
formaldehyde cross linked lysates were incubated with appro-
priate amount of antibodies or with unrelated IgG antibody as
a negative control, for 1 hour at 4uC. Then 20 ml protein A/G
agarose beads (Santa Cruz) were added to each sample and
incubated for 1 hour at 4uC. The beads were precipitated and
washed for 10 minutes with the RIPA modified lysis buffer.
Washing was repeated four times. All steps were performed with
mild agitation. SDS sample buffer was added to the beads after
the last wash, and then the samples were boiled, separated by
SDS-PAGE and either immunoblotted with the appropriate
antibodies or stained with the Coomassie blue based sensitive
staining (Imperial protein stain, Pierce) according to the
manufacturer’s instructions. For mass spectrometric analysis,
the protein bands were excised from the stained gel and
delivered to the Biological Mass Spectrometry Facility at
Weizmann Institute of Science or to the University of Kentucky
proteomics core facility.
For Western blot analysis, protein samples were separated on
12% SDS-polyacrylamide gels, then transferred to nitrocellulose
membranes (BioTrace NT, Pall Inc.). The efficiency of transfer
was monitored by Ponceau-S (Sigma) staining. The membranes
were blocked for 1 h at RT with 5% milk (Sigma) in TTBS.
Incubation with the primary antibodies was for 1 h at RT or
overnight at 4uC. The membranes were washed three times with
TTBS for 5 minutes each then incubated with secondary antibody
for 1 hour at room temperature and subsequently washed with
TTBS four times for 5 minutes. Blots were exposed and developed
using the ECL blot detection reagent EZ-ECL (Biochemical
Industries) using Chemi Doc XRS+ digital camera with Image
Lab software. Western blot analyses for CaM in cell lysates were
performed similarly except that PVDF membranes were used
(with 20 mg of protein) and the membrane was developed using
NBT/BCIP (Sigma).
Expression and Purification of GST-Fusion Proteins
All the GST-fusion proteins were produced in Rosetta E.Coli
cells, growing in YTx2 medium, by induction with 0.1 mM IPTG
for three hours. Cells were lysed in the presence of 100 mM PMSF
with seven 20-s sonicator pulses 50% duty on ice. The resulting
lysate was centrifuged for 40 min at 12,000 rpm at 4uC. The
proteins were then purified from the lysate by binding to
glutathione-Sepharose 4B beads (Amersham Biosciences) accord-
ing to the manufacturer’s instructions; the GST-fusion proteins
were eluted with 30 mM glutathione, 50 mM Tris-HCl, pH 7.5,
and 120 mM NaCl.
Pull Down Assays
Lysate from HeLa cells transfected with Myc-CaM KMT or
Myc plasmid containing 3 mg protein were incubated with 20 ul
glutathione sepharose beads conjugated to 15 mg purified GST-
Hsp90 N, M, and C-terminal fragments or GST as a negative
control for overnight, at 4uC, with mild agitation. The beads were
precipitated and washed four times for 10 minutes with the RIPA
modified lysis buffer. Washing was repeated 4 times. Western blot
was performed using anti-Myc antibody.
Characterization of CaM KMT
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CaM Methylation Assays
Cell lysates from lymphoblastoid cells (harvested as described
above) were obtained by sonication in 50 mM Tris pH=7.5,
150 mM NaCl, 5 mM DTT, 0.01% Triton X-100, 1 mM PMSF
(eight 5 second pulses at 60% power on ice). The lysates were then
clarified by centrifugation at 16000 g at 4uC for 10 min. The
assays, in a final volume of 100 ml, contained 100 mM bicine
pH 8, 150 mM KCl, 2 mM MgCl2, 2.5 mM MnCl2, 0.01%
Triton X-100, 100 mM CaCl2, 2 mM DTT, 10 mCi [3H-methyl]
AdoMet (70–80 m Ci mmol21,from PerkinElmer), 5 mg of human
CaM KMT (HsCaM KMT), expressed using a SUMO vector and
purified according to [5], and 100 mg of total protein from cell
lysates. All reactions were performed at 37uC for 2 hours and
terminated by protein precipitation with 25 volumes of 10% (v/v)
trichloroacetic acid. The precipitated protein pellet was dissolved
in 150 ml of 0.1 N NaOH and precipitated again with the same
volume of trichloroacetic acid prior being dissolved in SDS-PAGE
loading buffer. The samples were electrophoresed on 12.5% SDS-
PAGE gels, and transferred to a PVDF membrane prior to
phosphorimage analyses.
Results
CaM KMT is Alternatively Transcribed in 2p21 Deletion
Syndrome Patients
The CaM KMT gene has two splicing variants that share the
first three exons (Fig. 1A). CaM KMTsh, the short variant, has
a 4th exon, whereas the long variant has eight additional exons and
we demonstrated that it has calmodulin-lysine N-methyltransferase
activity [5]. We previously reported that in accordance with
deletion of all the 59 sequence, including the promoter region, first
exon and additional 300 bp into the first intron of CaM KMT in
2p21 deletion syndrome, the gene is not expressed in lympho-
blastoid cells from the patients when testing with primers from the
first exon. We have also demonstrated that in normal individuals
both splice variants of CaM KMT have a broad transcription
profile, including tissues that are affected in the 2p21 deletion
syndrome: muscle, brain, testis and kidney [2]. To determine
whether transcription of CaM KMT may be salvaged in the
patients by the use of alternative exons outside the deletion region
and more specifically in the interval of 313.9 Kb between the 3rd
and 4th exons of the long isoforms we performed 59RACE PCR
on cDNA derived from patients’ lymphoblastoid cells using
a primer positioned at the border of the 5th and 6th exons and
a nested primer in the 4th exon of the long CaM KMT isoform.
RACE-PCR products were subcloned into pGEM-T and
sequenced. The results revealed two new CaM KMT splice
variants derived from the patients’ cells (Fig. 1A). The first exon of
the CaM KMT-1 variant is in the genomic interval between the
3rd and 4th exons (position chr2:44776694–44776867 on hg19),
its size is 174 bp and it connects to the known 4th exon (Fig. 1C).
Alignment of this exon with the genomic sequence displays the
AG/GT consensus for splice site at the intron–exon boundaries.
To assess whether the expression of this novel isoform CaM
KMT-1 is exclusive to the patients, we tested its production in
lymphoblastoid cells of a normal control and in several human
tissues. We performed RT-PCR with a 59 primer in the new exon
and a 39 primer in the 4th exon of the long CaM KMT. As shown
in Fig. 1B, the new variant is also expressed in the normal control
lymphoblastoid cells and in brain, testis and muscle. The second
new variant, termed CaM KMT-2, starts exactly at the beginning
of the 2nd exon of CaM KMT and continues to the last exon of
the long isoform. To verify whether these new transcripts code for
proteins we searched for open reading frames (ORFs) in the newly
identified isoforms and found none. Both variants encode the ORF
known for CaM KMT; the first methionine is in the known 4th
exon resulting in a length of 167 amino acids (Fig. 1C). However,
this initiation codon is not in a good Kozak consensus sequence,
missing both most important nucleotides G, after the methionine
codon and A, three nucleotides before the methionine that
determine the efficiency of mRNA translation [12] (Fig. 1C).
These results may suggest that no additional CaM KMT protein is
expected to be produced.
The Absence of CaM KMT Causes Accumulation of
Hypomethylated Calmodulin in 2p21 Deletion Syndrome
Patients
It has been reported that the methylation state of CaM changes
in developmental and tissue dependent manners potentially
affecting the interaction of CaM with target proteins, thus
influencing various cellular processes [5,13–15]. Since the 2p21
deletion syndrome patients do not express CaM KMT, we
evaluated the methylation status of CaM in two 2p21 deletion
syndrome patients’ lymphoblastoid cells. We performed an in vitro
methylation assay using lysates from lymphoblastoid cells from
patients and normal controls as a source for CaM as a substrate.
The lysates were incubated with purified SUMO-HsCaM KMT
and [3H-methyl] AdoMet as the methyl donor. A protein of the
molecular size of CaM was radioactively labeled in patient cells’
lysates, while this labeling was absent in normal controls (Fig. 2A).
We confirmed that the methylation occurred on CaM and not on
another cellular protein with a similar molecular mass, by
depletion of the radiolabeled band by chromatography on
phenyl-sepharose that binds CaM [16] (Fig. 2B), immunoblotting
analysis for CaM that demonstrated comparable quantity of CaM
in patients and control cells (Fig. 2C) and a reduced amount of
CaM after phenyl sepharose depletion, with still comparable
amount in patient and normal individual (Fig. 2D). MS/MS
analysis of a non-radiolabeled immuno-reactive band from
a duplicate experiment that shows 60% coverage of the poly-
peptide sequence for CaM including un-methylated Lys-115 from
the patients’ cells is reported in Fig. 2F. Finally, to prove that CaM
from patient cells could still be methylated by SUMO-HsCaM
KMT in vitro, we purified CaM from patients cells by phenyl-
sepharose and then incubated it with HsCaM KMT and [3H-
methyl] AdoMet and a strong radiolabel incorporation was detected
(Fig. 2E). An additional analysis of the methylation status of CaM
in patient and normal cells was conducted by mass spectrometry
on CaMs after phenyl sepharose purification. A mass of 1349Da
was detected in the patient cells (fig. S1A), corresponding to
peptide L116-R126, obviously a product of tryptic digestion at
K115, and another peptide of 2359Da corresponding to H106-
R126 without methyl groups on K115. The absence of methyl
groups was also confirmed by the absence of any mass
corresponding to peptide H106-R126 containing trimethyllysine.
CaM from normal individual (Fig. S1B) was demonstrated to be
fully methylated, presenting peptides corresponding to sequence
H106-R126 containing a fully methylated K115 and different level
of oxidation on methionines (peptides 2417Da and 2433Da). No
peptides containing unmethylated K115 were visible (fig. S1B and
S1C). These results show that the deletion of CaM KMT in
patients promotes accumulation of hypomethylated CaM that can
be methylated in vitro by HsCaM KMT, and further demonstrate
the absence of any compensatory cellular mechanisms for
methylation of Lys-115 in CaM.
When CaM KMT was added to cell lysates in the presence of
[3H-methyl] AdoMet we observed radiolabel incorporation into
HsCaM KMT (Fig. 2B, arrow). This may be self-methylation since
Characterization of CaM KMT
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incubation of GST-CaM KMT fusion protein purified from
bacteria with [3H-methyl] AdoMet resulted in labeling of GST-
CaM KMT (see Figure S2).
The Subcellular Localization of the CaM KMT Proteins
To determine the subcellular localization of CaM KMT we
subcloned it into pEGPF-N1 expression vector, which produce
CaM KMT in-fusion with the C-terminal GFP tag and studied the
cellular localization by confocal microscopy. Transfection of the
CaM KMT-GFP into HeLa cells, showed both cytoplasmic and
nuclear localization which was distinct from the diffused cellular
localization of GFP control construct (Fig. 3A, B). We concluded
that CaM KMT has nuclear and cytoplasmic distribution. We also
determined the subcellular localization of the short CaM KMT
variant, encoding a protein of 132 amino acids. This variant
contains the same three 59 exons as CaM KMT and an additional
4th exon that lacks the methyltransferase domain. COS-7 cells
were transfected with the GFP-CaM KMTsh construct and
analyzed by fluorescence microscopy. GFP-CaM KMTsh over-
expression revealed a discrete localization near the nucleus, similar
to the Golgi apparatus localization. To verify if CaM KMTsh was
sublocalized to the Golgi, COS-7 transfected cells with the GFP-
CaM KMTsh were immunostained with the Golgi marker, anti-
58 k antibody. The fluorescent signals from the two proteins
overlapped considerably, indicating that GFP-CaM KMT could
localize to the Golgi (Fig. 3D). These results suggest that the short
CaM KMT variant has a distinct subcellular localization from the
full length variant.
Using the affinity-purified polyclonal anti-CaM KMT antibody,
we examined endogenous CaM KMT expression in different
mouse tissues (Fig. 3C). Protein bands with the expected molecular
masses of CaM KMT (36 kDa) were detected in most of the tissues
examined, with the highest expression in the brain and muscle.
The short variant could not be detected. These data support that
CaM KMT is a ubiquitously expressed protein, including the high
expression in the tissues affected in 2p21 deletion syndrome.
Figure 1. Identification of alternative CaM KMT variants and their expression pattern. (A) Schematic representation of the new splice
variants CaM KMT-1 and CaM KMT-2 that were identified by 59RACE-PCR, and their positions relative to the known full length CaM KMT and short CaM
KMTsh variants. The top of the figure shows the position on chromosome 2 and the ruler of the bases according to genome assembly hg19. The site
of the 2p21 deletion is marked by an arrow. (B) Verification of the transcription of the CaM KMT-1 variant by RT-PCR in the lymphoblastoid cells from
patients and controls as well as in normal human tissues. The 59 primer was localized in the newly discovered exon and 39 primer in 4th exon of CaM
KMT. The identity of the products was validated by sequencing. The arrow points to the products of an expected size of 287 bp. -, no cDNA; Lm,
lymphoblastoid cells. (C) The sequence of the novel mRNA CaM KMT -1 isoform. Bold bases represent the sequence of the novel exon directly
connected to the sequence of the 4th known exon that is marked by an arrow. The open reading frame is underlined and the start codon is shown in
uppercase with Kozak consensus sequence shown in bold italic. The stop codon is shown in bold uppercase.
doi:10.1371/journal.pone.0052425.g001
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CaM KMT Interacts with Hsp90 Molecular Chaperon
To search for cellular proteins that specifically interact with
CaM KMT, lysates of HEK293 cells expressing FLAG-CaM
KMT were immunoprecipitated with anti-FLAG antibody. The
immunoprecipitates were Coomassie stained and one predomi-
nant protein band of about 90 kDa that appeared to specifically
co-purify with FLAG-CaM KMT could be distinguished. The
other less intensive bands of,70 kDa were revealed as nonspecific
in additional experiments (Fig. 4A). The 90 kDa band was excised
from the Coomassie stained gel, subjected to mass spectrometry
analysis and identified as the alpha and beta isoforms of the
molecular chaperon Hsp90. The sequenced peptides represent
26% coverage of the amino acid sequences and allow differenti-
ating between the a and b isoforms of Hsp90 (Fig. 4B) suggesting
that both of them interact with CaM KMT. Human Hsp90a and
Hsp90b homologs show approximately 85% identity to each other
with molecular masses of 84 and 83 kDa, respectively. These
homologs exhibit similar participation in multi-chaperon com-
plexes and interact with the same substrates under normal
conditions [17]. To ascertain the association between CaM
KMT and Hsp90 we transiently transfected HEK293 cells with
Myc-CaM KMT and performed immunoprecipitation with
a monoclonal anti-Myc antibody. The immunoprecipitates were
subjected to SDS-PAGE followed by immunoblotting with anti-
Hsp90 a/b antibody. In agreement with the mass spectrometry
results CaM KMT was found to bind Hsp90 (Fig. 4 C-left).
Conversely, the transfected cell lysates were precipitated with anti-
Hsp90 antibody and then probed with anti-Myc (Fig. 4 C-right).
Thus, CaM KMT and Hsp90 proteins are suggested to be in
a protein complex.
CaM KMT Binds to the Middle Domain of Hsp90
Sequence alignments and proteolytic digests of Hsp90 have
shown a modular structure of three domains: the N-terminal is an
ATP binding domain; the C-terminal domain mediates the
dimerization of the chaperons and the middle domain acts as
a discriminator between different types of client and co-chaperon
proteins [18,19]. Therefore, we next asked whether the interaction
Figure 2. Analyses of the methylation status and relative amounts of CaM in lymphoblastoid cell lysates from a patient affected by
the 2p21 deletion syndrome. (A) Phosphorimage of cell lysates from two 2p21 deletion syndrome patients and wild type individuals incubated in
the presence of [3H-methyl] AdoMet with and without the addition of HsCaM KMT. (B) Phosphorimage as in panel (A) but after reduction in the level
of CaM by treatment of the cell lysates with phenyl sepharose. Molecular mass markers in kDa are indicated between A and B. (C) Western blot
performed with anti-CaM antibody to verify the presence of similar amounts of CaM in the 2p21 deletion syndrome patient and wild type individuals.
(D) Western blot performed as in panel (C) on cell lysates after partial removal of CaM with phenyl sepharose. (E) Phosphorimage showing
methylation of phenyl sepharose-bound CaM removed from 2p21 deletion syndrome patients cell lysates by the addition of HsCaM KMT and [3H-
methyl] AdoMet. Molecular mass markers in kDa are indicated on the right. (F) Identification of the protein radiolabeled by incubation with [3H-
methyl] AdoMet and HsCaM KMT in panel (A) as CaM by MS/MS analysis. Peptides identified after tryptic digestion are shown in bold, approximately
60% of the entire CaM sequence was identified. The arrow indicates the position of HsCaM KMT.
doi:10.1371/journal.pone.0052425.g002
Characterization of CaM KMT
PLOS ONE | www.plosone.org 6 December 2012 | Volume 7 | Issue 12 | e52425
Figure 3. Subcellular localization of the CaM KMT-GFP fusion proteins in transiently transfected cells and expression in mouse
tissues. (A) GFP- CaM KMT is localized in the cytoplasm and the nucleus. Confocal images of HeLa cells expressing CaM KMT-GFP (green), nuclear
staining by DAPI (blue) and the merged image. (B) The expression of the GFP only. Confocal images of HeLa cells expressing GFP (green), staining of
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between CaM KMT and Hsp90 is direct and which of the Hsp90
domains binds CaM KMT. To determine the binding site we
performed pull down assays with GST constructs of each of the
three Hsp90 domains. The GST-Hsp90 fragments: Hsp90N: the
N-terminal domain (9–238aa), Hsp90M: the middle domain (272–
617aa) and Hsp90C: C-terminal domain (629–732aa) were
expressed in bacteria and affinity purified (Fig. 5A). HeLa cells
were transfected with Myc-CaM KMT, lysed and then incubated
with the GST-Hsp90 domains immobilized to glutathione agarose
beads. Immunoblotting analysis with anti-Myc antibody demon-
strated that CaM KMT binds specifically with the Hsp90 middle
domain (Fig. 5B). This result indicates direct interaction of CaM
KMT with the middle domain of Hsp90.
Hsp90 is Required to Stabilize CaM KMT Protein
The Hsp90 chaperone machinery comprises numerous partner
proteins: the scaffold proteins for the Hsp90 complexes and co-
chaperons influence the affinity of the chaperon to substrates by
regulation of ATPase cycle, recruit chaperons to specific proteins
or assist in protein folding directly. Another group of Hsp90
interacting proteins is substrates or client proteins which folding,
stability and conformational maturation are affected by the
chaperon activity. It has been reported that several client proteins
such as Akt1, Aha1, Hch1, and Src bind to the middle domain of
Hsp90 whereas co-chaperons bind mostly to the C-terminal
domain [20–23].
Therefore, the fact that CaM KMT physically associated with
the middle domain of Hsp90, encouraged us to ask whether it is
a new client protein. For this purpose, we inhibited Hsp90 ATPase
dependent chaperon activity with geldanamycin (GA) and tested
the stability of CaM KMT. Geldanamycin is a specific antagonist
of Hsp90 that binds specifically to the N-terminal ATP binding site
of Hsp90, destabilizing the association between Hsp90 and its
client proteins resulting in degradation of the client proteins via the
proteasome pathway [24,25]. We transiently transfected HeLa
cells with Myc-CaM KMT for 24 h. At the time of the transfection
we added increasing concentrations geldanamycin (GA) for 24 h.
Then total cell extracts were analyzed by Western blotting with
anti-Myc. As controls of equal loading of proteins we probed the
membrane with anti-GAPDH antibody. As shown in Fig. 6A, GA
induced a significant decline of CaMKMT protein levels in a dose-
dependent manner in comparison to untreated cells. To verify that
the sensitivity of CaM KMT to degradation is not tag dependent,
HeLa cells were transiently transfected with CaM KMT tagged at
C-terminus with FLAG tag and subsequently exposed to GA. The
result demonstrated that the tag has no effect on GA induced loss
of CaM KMT protein (Fig. 6B). The effect of GA was specific,
since it has no effect on the GAPDH protein levels. These results
suggest that CaM KMT is a novel client protein as it depends on
Hsp90 chaperon activity for the stability and down regulated by
Hsp90 inhibition.
Discussion
We have previously reported an autosomal recessive 2p21
deletion syndrome in which three genes (SLC3A1, PREPL, PP2Cb)
and the first exon of CaM KMT are deleted. We demonstrated that
the deletion abolished the transcript of CaM KMT in the 2p21
deletion syndrome patients, while the gene is ubiquitously
transcribed in human normal tissues such as: brain, liver, colon,
muscle and lung. The broad transcription profile of CaM KMT
gene includes the tissues affected in the 2p21 deletion syndrome
such as: muscle, brain, testis and kidney, suggesting a role for CaM
KMT absence in 2p21 deletion syndrome clinical manifestations
of the patients.
Here we identified two alternatively transcribed isoforms by
59RACE-PCR experiments. These transcripts are located outside
the deletion borders, thus, they are expressed in the patients’ cells
as well as in several normal, human tissues. These new transcripts
are not predicted to produce truncated CaM KMT proteins since
they do not possess an initiator methionine codon within a good
Kozak consensus sequence. However, we cannot rule out, the
possibility that these transcripts could be translated since trans-
lational initiation has been shown for other proteins lacking the
canonical motifs in their initiation codons [26].
We show here for the first time that loss of CaM KMT gene
expression in 2p21 deletion syndrome patients results in an
accumulation of hypomethylated CaM. This result proposes that
CaM KMT is the major methyltransferase of CaM and there are
no compensatory mechanisms for this activity in the patients. The
absence of the CaM KMT activity can thus contribute to the
mental retardation and mitochondrial defect observed in the 2p21
deletion patients but not in the hypotonia cystinuria patients with
the absence of only the SLC3A1, PREPL alone. The results suggest
that the methylation status of CaM may play a role in affecting
CaM-dependent signaling pathways, and proteins with domains
capable of reading protein methylation status have been described
[27].
The importance of the methylation status of CaM has been
ambiguous. The absence of methylation has been reported not to
affect cell growth and viability in a chicken cell line [28]. However,
the methylation status of CaM can vary in a developmentally
specific manner [13,29]. While the activity of some enzymes are
directly affected by the methylation status of CaM such as plant
NAD kinase [30], others like myosin light chain are not [30,31].
Considering the relatively high number of proteins known to
interact with CaM (over 300) there is likely many proteins that
interact differentially with methylated versus non-methylated
forms of CaM. We also noted an apparent automethylation of
CaM KMT but do not know the site of methylation or whether or
not it carries any biological significance. This type of autocatalytic
activity has been shown for several enzymes, and it can affect
different protein functions. For instance, inhibition of enzymatic
activity by automethylation was identified in the DNA-cytosine-5-
methyltransferase (m5C-MTase) M.BspRI [32] as well as re-
pression for Metnase, a human SET and transposase domain
protein that methylates histone H3 and promotes DNA double-
strand break repair [33]. A different effect of automethylation is
seen for histone H3 methyltransferase G9a. The autocatalytic G9a
methylation was found to be important for protein-protein
interactions. The methylation creates a binding site which
mediates in vivo interaction with the epigenetic regulator hetero-
nuclei by DAPI (blue), and the merged image. (C) Cell lysates (100 mg of protein/lane) from mouse muscle, heart, liver, kidney, brain and spleen were
resolved by SDS-PAGE, transferred to a nitrocellulose membrane, and blotted with an affinity purified polyclonal anti-CaM KMT antibody (1) immune
and (2) pre-immune serum. Anti-HSP90 antibody served for protein loading control, 100 mg protein/lane were analyzed. Positions of CaM KMT and
HSP-90 are indicated by the arrows. (D) GFP- CaM KMTsh is localized to the Golgi. COS-7 cells were transfected with the GFP- CaM KMT short variant
and immunostained with primary antibodies against Golgi 58 k protein. GFP-CaM KMTsh was detected directly by the fluorescence microscopy
(green) and 58 k Golgi protein was visualised with Cy3-labeled secondary antibodies (red). Cells nuclei were stained with DAPI (blue). Shown is the
merged image presenting colocalization (in yellow) of the GFP-CaM KMT short protein with Golgi apparatus.
doi:10.1371/journal.pone.0052425.g003
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chromatin protein 1 (HP1) [34,35]. The significance of the
automethylation is not known, for Dnmt3a it was suggested to be
either a regulatory mechanism which could inactivate unused
DNA methyltransferases in the cell, or simply be an aberrant side
reaction caused by the high methyl group transfer potential of
AdoMet [36].
Our analysis of the subcellular localization of CaM KMT within
the cell showed both cytoplasmic and nuclear localization. Taking
together these observations suggests CaM KMT activity probably
takes place in both compartments. The distribution of CaM KMT
in the nucleus and the cytoplasm seems equal in all cells,
suggesting that the shuttling is not a cell cycle dependent event.
However, the purpose and the mechanism of the shuttling into the
nucleus remains to be further investigated. Intracellular distribu-
tion of calmodulin was also found to be both nuclear and
cytoplasmic. Little is known about how the subcellular localization
of calmodulin is regulated, a process that, by itself, could regulate
calmodulin functions [37]. Calmodulin is the major calcium sensor
in neurons when present in the cytoplasm [38]. While in the
nucleus, calmodulin binds to some co-transcription factors, like
BAF-57, a protein member of a complex involved in the repression
of neuronal specific genes [39]. The mental retardation in the
patients lacking CaM KMT may suggest an important role for
CaM KMT in neuron functions. Since in the 2p21 deletion
syndrome patients we previously reported reduced activity of
mitochondrial respiratory complexes, except complex II [1], it was
possible that CaM KMT will have a mitochondrial localization
(we have tested subcellular expression of all other genes deleted in
the 2p21 deletion syndrome and none localizes to the mitochon-
dria, not reported). It could localize similar to C20orf7, a predicted
methyltransferase that is essential for complex 1 assembly or
maintenance and may methylate NDUFB3, complex subunit.
C20orf7is peripherally associated with the matrix face of the
mitochondrial inner membrane [40].
CaM KMTsh-GFP fusion protein was found to localize to the
perinuclear structure resembling that of the Golgi complex in
COS-7 and HeLa cells. However, the precise function of this
variant remains obscure. The 4th exon specific to this variant is
not evolutionary conserved.
Figure 4. CaM KMT interacts with Hsp90. (A) Lysates of HEK293 cells transiently transfected with FLAG- CaM KMT or FLAG were
immunoprecipitated with anti-FLAG antibody. The precipitated proteins were subjected to SDS-PAGE and then Coomassie stained. Molecular mass
markers in kDa are indicated on the left. The band of approximately 90 kDa (shown with the asterisk) was excised from the gel, and analyzed by mass
spectrometry. The heavy chains of the antibodies ,50 kDa, two nonspecific bound proteins about 70 kDa and FLAG-CaM KMT immunoprecipitated
protein were also observed. (B) Alignment of the protein sequences Hsp90a and HSP90b. The bold stretches of amino acids (26% of the protein
sequence) represent peptide sequences as identified by mass spectrometry in the NCBI data bank matching Hsp90a and Hsp90b. Diverse amino acids
in Hsp90a and Hsp90b, present in the sequenced peptides and enable to distinguish between the isoforms (shown in red). (C) CaM KMT and Hsp90
proteins immunoprecipitate each other.HEK293 cells were transiently transfected with Myc-CaM KMT or an empty Myc vector and 48 h after the
transfection, equal protein amounts of whole cell lysates were immunoprecipitated using an anti-Myc (left), anti-Hsp90 (right) and mock IgG antibody
(left) as a negative control. The immunoprecipitates were subjected to the Western blot analysis using anti-Myc and anti-Hsp90 antibody as indicated.
Equal protein amounts in the immunoprecipitation assays were demonstrated by analysis of 1% input. These experiments were repeated three times
with identical results.
doi:10.1371/journal.pone.0052425.g004
Figure 5. CaM KMT binds to the middle domain of Hsp90. (A) Schematic representation of the structural domains of human Hsp90 used in
these experiments (numbers refer to the sequence of human Hsp90a). (B) Binding of CaM KMT and the middle domain of the Hsp90. GST fused
Hsp90 fragments (10 mg protein) used in the pull-down experiments: GST- Hsp90N - N-terminal (9–236aa), GST- Hsp90M - middle domain (273–617aa),
GST- Hsp90C- C-terminal (629–732aa), were expressed in E.Coli, purified and immobilized to glutathione agarose beads. After overnight incubation
with Myc-CaM KMT transfected HEK293 cells’ lysates, the beads were washed and the bound proteins were subjected to SDS-PAGE. The membrane
was stained with ponceau red before immunoblotting to demonstrate similar quantities of GST-Hsp90. Immunoblotting with anti-Myc antibody
revealed that CaM KMT binds only the middle domain. Representative results from six independent experiments are shown.
doi:10.1371/journal.pone.0052425.g005
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Subsequent to the anti-CaM KMT polyclonal antibodies
generation, the CaM KMT expression was confirmed in various
mouse tissues: spleen, brain, kidney, liver, heart and muscle. These
results support the suggestion that CaM KMT is a ubiquitously
expressed protein, and highly expressed in the tissues affected in
2p21 deletion syndrome.
In this work we have shown that CaM KMT interacts with the
Hsp90 protein. Hsp90 is a molecular chaperone and the most
abundant heat shock protein under normal conditions. It exhibits
ATPase activity which is essential for its chaperone function.
Hsp90 binds to an array of client proteins that require its chaperon
function for their folding, stabilization, ligand binding and
activation. In addition, Hsp90 interacts with various types of co-
chaperones, which regulate the ATPase activity of Hsp90, mediate
the folding and activation of the client proteins, and direct Hsp90
to interact with specific client proteins [7]. Our mass spectrometry
results have shown that both isoforms, Hsp90a and Hsp90b,
interact with CaM KMT. We mapped the interaction of CaM
KMT with Hsp90 to the middle domain of Hsp90, showing that it
is a direct binding, by performing pull-down experiments with
Hsp90 purified fragments. The middle domain is known to act as
a discriminator between different types of Hsp90 interacting
proteins, mostly the client proteins [21]. To verify whether CaM
KMT is a co-chaperone or a client protein we inhibited the
ATPase chaperon activity of Hsp90 by geldanamycin. Since the
inhibition led to a significant decrease in CaM KMT protein levels
we concluded that CaM KMT is a novel Hsp90 client protein.
Another methyltransferase protein, Smyd3, was shown to interact
with Hsp90 and this association was demonstrated to enhance the
catalytic activity of Smyd3 [41]. Presumably, the biological activity
of CaM KMT is also regulated by Hsp90 through a mechanism
which requires CaM KMT-Hsp90 interaction. We conclude that
CaM KMT is a novel, direct middle domain binding client protein
and Hsp90 plays a general role in its expression levels. In this study
we demonstrated that the novel CaM Lys-115 methyltransferase
CaM KMT has a cytoplasmic and nuclear localization. The loss of
CaM KMT results in hypomethylation status of CaM and we found
that CaM KMT is a novel Hsp90 client protein. This study
demonstrates the first step to provide basic information on CaM
KMT that is deleted in patients of two contiguous gene deletion
syndromes.
Supporting Information
Figure S1 Mass spectrometric analyses of CaM purified
from lymphoblastoid cell lines of 2p21 deletion patients
and normal individuals. CaM purified using a phenyl
sepharose resin was subjected to trypsin digestion and peptide
analysis. CaM extracted from 2p21 patients (A) showed one
peptide corresponding to the digested fragment L116-R126, an
indication that K115 was not methylated, and one peptide
corresponding to H107-R126, in which the trypsin cut was
overpassed, but also shows that K115 is not methylated. The
missing peptides corresponding to the same sequence H107-R126
if trimethyllysine was present are reported in between parenthesis
and in a smaller font. The expected region in the spectrum where
their masses should be visible are indicated by the arched shape.
The analysis on CaM from normal individual (B) showed 2
peptides corresponding to the sequence H107-R126 containing
one or two oxygens (indicated in figure by ox), both trimethylated
at position 115 (K3Me). The peptides seen in panel A (not
containing the trimethyl group on K115) were not detected in the
normal individual, as also demonstrated by panel C where the
peptide L116-R126 is not visible in the wild type CaM spectrum.
(TIF)
Figure 6. Geldanamycin induces degradation of the CaM KMT. HeLa cells transfected with Myc-CaM KMT (A) and with FLAG-CaM KMT (B)
cells were treated with increasing concentrations of GA for 24 h, followed by immunoblotting with monoclonal antibodies anti-Myc (A) and anti-
FLAG (B) to examine protein levels of CaM KMT. Western blot with anti-GAPDH antibody was used as proteins’ loading control. The results shown in
(A) are representative of four independent experiments. The results shown in (B) are representative of two independent experiments.
doi:10.1371/journal.pone.0052425.g006
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Figure S2 Automethylation in-vitro of CaM KMT. GST-
CaM KMT protein (10 mg) was incubated with 5 mCi [3H-methyl]
AdoMet (70–80 Ci mmol21 [3H-methyl] AdoMet (from PerkinEl-
mer), in 100 mM sodium phosphate buffer, pH 7.4, at 37uC for 1
hour. In control reaction unlabeled (cold) AdoMet (Sigma) was
also added to a final concentration of 100 mM. After incubation,
the reaction was terminated by the addition of SDS sample buffer,
and the samples were subjected to 12% SDS-PAGE, the gel was
stained with Coomassie blue staining (Imperial protein stain kit,
Pierce). For fluorography, gels were treated with 2,5-diphenylox-
azole (PPO) (Sigma), vacuum dried at 70uC and exposed to X-ray
scientific imaging film (Kodak, MS ) at 280uC for 7–14 days.
(TIF)
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